The SURTAVI trial has become the second major face-off between transcatheter and surgical aortic valve replacement (TAVR and SAVR, respectively), after PARTNER 2A, to show parity in 5-year clinical outcomes in patients with severe, symptomatic aortic stenosis at intermediate surgical risk. The new SURTAVI results, like those from the other trial that used different TAVR valves,